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Abstract
To determine health-related quality of life (HRQOL) after radical retropubic prostatectomy
(RRP) or permanent prostate brachytherapy (BT), third party-conducted QOL surveys were prospec-
tively compared. Between 2004 and 2005, 37 patients underwent RRP and 36 were treated with
BT. A QOL survey consisting of the Medical Outcomes Study 36-Item Short Form (SF-36), the
University of California, Los Angeles, Prostate Cancer Index (UCLA-PCI) and the International
Prostate Symptoms Score (IPSS) was completed prospectively by a research coordinator at base-
line, and at 1, 3, 6 and 12 months after treatment. The RRP patients scored well in general QOL
except at 1 month after surgery, with their mental health better than at baseline by 6 months after
surgery. Disease-specific QOL in RRP patients received a low score at 1 month for both urinary
and sexual function, though urinary function rapidly recovered to baseline levels. BT patient QOL
was not affected by the therapy except in the IPSS score. However, general and mental health
scores in BT patients were inferior to those in RRP patients. This prospective study revealed dif-
ferences in QOL after RRP and BT. These results will be helpful in making treatment decisions.
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To determine health-related quality of life (HRQOL) after radical retropubic prostatectomy (RRP) or 
permanent prostate brachytherapy (BT),  third party-conducted QOL surveys were prospectively com-
pared.  Between 2004 and 2005,  37 patients underwent RRP and 36 were treated with BT.  A QOL 
survey consisting of the Medical Outcomes Study 36-Item Short Form (SF-36),  the University of 
California,  Los Angeles,  Prostate Cancer Index (UCLA-PCI) and the International Prostate Symptoms 
Score (IPSS) was completed prospectively by a research coordinator at baseline,  and at 1,  3,  6 and 12 
months after treatment.  The RRP patients scored well in general QOL except at 1 month after sur-
gery,  with their mental health better than at baseline by 6 months after surgery.  Disease-speciﬁc QOL 
in RRP patients received a low score at 1 month for both urinary and sexual function,  though urinary 
function rapidly recovered to baseline levels.  BT patient QOL was not aﬀected by the therapy except 
in the IPSS score.  However,  general and mental health scores in BT patients were inferior to those in 
RRP patients.  This prospective study revealed diﬀerences in QOL after RRP and BT.  These results 
will be helpful in making treatment decisions.
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adical retropubic prostatectomy (RRP) is con-
sidered a standard,  safe and eﬀective treatment 
for localized prostate cancer.  Prostate brachyther-
apy (BT) is also accepted as a treatment option for 
localized prostate cancer in selected patients.  The 
outcomes of both of these treatments for low-risk 
localized prostate cancer are the same according to 
recently published retrospective studies [1,  2].  
Therefore,  the basis on which primary therapy is 
selected has shifted toward the consideration of 
health-related quality of life (HRQOL).  In previous 
studies,  few changes in general HRQOL after RRP or 
BT have been reported [3ﾝ6].  In contrast,  reports 
show worse disease-speciﬁc QOL,  with compromised 
bowel function and urinary irritative symptoms in the 
BT group,  and urinary incontinence and sexual dys-
function in the RRP group [3,  6,  7].  Nevertheless,  
few studies have used a neutral third-party research 
R
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coordinator with no bias toward either the patient or 
the clinician to compare RRP and BT outcomes.  Some 
authors note that the method of data collection might 
cause a signiﬁcant diﬀerence in reported QOL,  with 
patients tending to minimize complications when 
speaking to their surgeons and the surgeon-inter-
viewer,  in turn,  minimizing adverse outcomes [8,  9].  
To avert this bias in the present study,  we assessed 
HRQOL as reported by the patients directly to a 
research coordinator.  Furthermore,  in order to 
obtain the most objective information possible,  the 
operating surgeons were not involved with any compo-
nent of data acquisition or entry.
Materials and Methods
　 Between January 2004 and March 2005,  we 
obtained informed consent for this study from all 73 
patients treated by either RRP (n＝37) or BT (n＝36) 
for localized prostate cancer in our institutes.  The 
patients who underwent RRP or BT received stan-
dardized explanations of these treatments,  including 
descriptions of the procedures,  expectable beneﬁts 
and possible complications [10],  and each patient 
selected his own therapy without our recommendation 
as to which was better.  The indications for RRP were 
age up to 75 years,  T1 to T2,  any Gleason score,  and 
no limit on prostate-speciﬁc antigen (PSA) level.  The 
nerve-sparing technique was performed if the patient 
wanted to preserve his sexual function.  The indica-
tions for a nerve-sparing procedure depended on pre-
operative (number and Gleason score of the positive 
biopsy cores,  PSA level and patient preference) and 
intraoperative factors,  prioritizing cancer control.  
RRP was performed using Walshʼs technique by 2 
urologists or staﬀ under their supervision.  Both sur-
geons had considerable experience with the retropubic 
approach prior to the study.
　 The primary indication for BT was T1c to T2,  a 
Gleason score of 6 or 7 (primary grade 3),  and PSA 
under 10ng/ml.  Patients treated with BT received 
145Gy to the prostate with an I-125 seed using a 
modiﬁed peripheral loading technique via a transrectal 
ultrasound-guided transperineal approach [10].  Dur-
ing this study,  we performed BT by the pre-planned 
method.
　 We assessed general HRQOL by the Medical 
Outcomes Study 36-Item Short Form (SF-36) [11],  
which covers 8 domains: 4 physical and 4 emotional.  
Prostate-speciﬁc HRQOL was assessed by the Uni-
versity of California,  Los Angeles,  Prostate Cancer 
Index (UCLA-PCI),  a 20-item questionnaire that 
quantiﬁes prostate cancer-speciﬁc HRQOL in 6 sepa-
rate domains [12].  In addition,  the International 
Prostate Symptom Score (IPSS) questionnaire was 
used to assess lower urinary symptoms.  All patients 
were informed of their cancer diagnosis by their 
urologist before being asked to answer the HRQOL 
questionnaires by a research coordinator.  Every 
patient who agreed to participate in this study 
received from the research coordinator a question-
naire,  an informed consent form and a prepaid enve-
lope in which to return the questionnaire to the third 
party.  The questionnaires were administered at 5 
points: the baseline survey was conducted within 1 
week before surgery or the initiation of BT,  and fol-
low-up surveys were conducted at 1,  3,  6 and 12 
months after treatment.  All scales of the SF-36 and 
UCLA-PCI were linearly transformed to a scale of 0 
(lowest) to 100 (highest).
　 Group comparisons were made using the Mann-
Whitney U-test and the chi-square test.  P＜0.05 was 
considered to be signiﬁcant.  This study was approved 
by the Institutional Review Board of our hospital.  
Written informed consent was obtained from all 
patients before the initiation of treatment.
Results
　 Surveys were returned by all patients.  The aver-
age answer rate of each survey was 92.4ｵ for RRP 
patients and 92.2ｵ for BT patients.  The median 
patient age was 67.0 years in both groups.  There was 
no statistical diﬀerence in clinical stage or PSA level 
between the 2 groups.  In contrast,  the distribution of 
Gleason scores (higher than 7) between the groups 
showed a statistical diﬀerence.  Neoadjuvant androgen 
deprivation therapy was performed in 13 patients from 
the BT group and in 3 from the RRP group.  All of 
these patients discontinued hormone therapy after 
RRP or BT.  Nerve-sparing surgery was performed in 
13 patients.  After 12 months,  3 RRP patients demon-
strated biochemical recurrence (PSA above 0.2ng/
ml).  No clinical recurrence occurred among any of the 
present patients (Table 1).
　 The longitudinal general HRQOL scores are shown 
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in Fig.  1.  There was no signiﬁcant diﬀerence in base-
line QOL scores between the groups.  In the RRP 
group,  the QOL scores of role-physical functioning,  
body pain,  social functioning and role-emotional func-
tioning at 1 month were worse than the baseline 
scores,  but recovered within 3 months,  while mental 
health scores improved over the baseline after 6 
months.  In the BT group,  QOL scores did not change.  
General health QOL scores at 12 months after treat-
ment were signiﬁcantly better in the RRP group than 
in the BT group.
　 The longitudinal results of the UCLA-PCI scores 
are shown in Fig.  2.  There was no signiﬁcant diﬀer-
ence in baseline scores between the RRP and BT 
groups.  In the RRP group,  urinary,  bowel,  and sex-
ual functioning were worse at 1 month after surgery.  
Although sexual function did not recover,  urinary and 
bowel functions recovered to baseline after 3 months.  
In the BT group,  changes in QOL scores were mini-
mal and showed no statistical diﬀerence.  At 1 month,  
urinary and sexual functions were worse in the RRP 
group than in the BT group.  Urinary function 
returned to baseline at 3 months,  though sexual func-
tioning in the RRP group remained worse than that in 
the BT group.
　 Longitudinal IPSS scores are shown in Fig.  3.  
There was no diﬀerence in baseline scores between 
the 2 groups.  Both groups showed worse scores than 
baseline at 1 month.  Although the RRP group recov-
ered to baseline at 3 months,  the low scores in the BT 
group continued for 6 months with gradual recovery 
by 12 months.
Discussion
　 Currently,  the most common therapeutic options 
for localized prostate cancer are RRP,  BT and exter-
nal radiation (three-dimensional conformal radiation 
therapy [3-D CRT]),  and the choice of treatment is 
based on the preference of the oncologist and/or 
patient.  Each of these interventions has undergone 
signiﬁcant reﬁnement in the last 10 years and can 
independently achieve higher than 95ｵ cancer-speciﬁc 
survival at 5 years after primary treatment in patients 
with low-risk cancer.  The choice of treatment is a 
diﬃcult one for both patients and oncologists,  and 
QOL after treatment has become increasingly impor-
tant in selecting treatment.  Many investigators have 
reported comparative studies of QOL after these 
treatments [3,  6,  7,  13ﾝ15]; however,  there have 
been few reports coordinated by a neutral third party 
standing in a neutral position between patient and cli-
nician.  Such a study would avert any bias caused by 
the tendency of patients to minimize complications 
when speaking to their surgeon or surgeon-inter-
viewer.  To the best of our knowledge,  the present 
study is the ﬁrst to make use of a research coordina-
tor involved from study entry to data collection with-
out involving the oncologist or operating surgeons.  
Although this is a small-number study,  the present 
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Table 1　 Patient characteristics for a RRP and BT
RRP BT p value
No. pts 37 36
Age (median) 54ﾝ75 (67) 53ﾝ76 (67) 0.679
Clinical stage
　　 T1 19 17 0.724
　　 T2 18 19
PSA (ng/ml)(median) 1.796ﾝ27.44 (8.31) 1.13ﾝ74 (7.73) 0.213
Gleason score
　　 6 14 21
0.031　　 7 18  7
　　8ﾝ9  5  8
Neoadjuvant hormone therapy  3 13 0.004
Nerve sparing
　　 yes 13 ―
　　 no 24 ―
Recurrence at 12 months  3  0 0.081
3
Kobuke et al.: Prospective longitudinal comparative study of health-related qual
Produced by The Berkeley Electronic Press, 2009




































































































Fig. 1　 A,  Longitudinal SF-36 scores in physical functioning,  role-physical functioning,  body pain and general health.  Role-physical 
functioning and body pain scores were worse at 3 months after surgery than at baseline in the RRP group (＊p less than 0.05).  The RRP 
group showed better general health scores than the BT group at 12 months after treatment (＊＊p＝0.031); B,  Longitudinal SF-36 scores in 
vitality,  social functioning,  role emotional functioning and mental health.  Social functioning and role emotional functioning were worse at 
3 months after surgery than at baseline in the RRP group.  The RRP group showed better mental health scores than at baseline at 6 and 12 
months after treatment (＊p less than 0.05).
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results accurately reﬂect patient QOL after RRP or 
BT.
　 In comparison to other studies conducted by treat-
ment providers,  the present results for RRP patients 
were consistent for general QOL,  which was good 
except at 1 month after surgery,  and for mental 
health,  which was better than baseline 6 months after 
surgery.  Our results for disease-speciﬁc QOL in RRP 
patients also showed low scores at 1 month in urinary 
function and sexual function.  However,  urinary func-
tion recovered to baseline more rapidly than previ-
ously reported in Japanese patients [6,  7],  despite 
diminished sexual functioning continuing to 12 months.  
Other investigators have reported [16,  17] that it 
may take 2 years or more for improvement in sexual 
function,  even in patients who underwent nerve-spar-
ing surgery.  Thus,  it can be concluded that RRP 
negatively aﬀects sexual function for at least the ﬁrst 


















































































Fig. 2　 A,  Longitudinal UCLA-PCI scores in urinary function.  In the RRP group,  urinary function was worse than baseline at 1 month 
(＊p less than 0.05),  but recovered to baseline after 3 months; B,  Longitudinal UCLA-PCI scores in bowel function.  In the RRP group,  
bowel function was worse than base line at 1 month (＊p less than 0.05),  but recovered to baseline after 3 months; C,  Longitudinal UCLA-
PCI scores in sexual function.  In the RRP group,  bowel function was worse than baseline at 1 month (＊p less than 0.001) and remained 
worse after 12 months.  In the BT group,  changes in QOL scores were slight.  Statistical diﬀerences between the RRP and BT groups were 
observed from 3 to 12 months after treatment (＊＊p less than 0.05).
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year after surgery,  even if it rules out the possibility 
of inﬂuence by neo-adjuvant hormonal therapy in a few 
patients.
　 The QOL of our BT patients was not aﬀected by 
the therapy except in the IPSS score.  The general 
and mental health in patients treated by BT were 
inferior to those in patients treated by RRP.  Patients 
treated by BT were perhaps not as satisﬁed as in prior 
reports [3,  6,  7,  13ﾝ15],  but the diﬀerence between 
our ﬁndings and those reports may be due to our data 
collection technique.  The present study is unique in 
creating a cohort design beginning before treatment 
with direct patient symptom reports using standard-
ized questionnaire items collected by independent 
observers rather than by the treatment providers.  
Third-party data collection protects against any poten-
tial tendency to minimize symptoms when questioned 
directly by the treating physician.  The BT group was 
inferior to the RRP group in both general and mental 
health,  possibly due to urinary and bowel irritability.  
For the survey of disease-speciﬁc QOL,  we used the 
UCLA-PCI.  For urinary function,  the UCLA-PCI 
focuses primarily on urinary incontinence.  Therefore,  
urinary irritability might have been underestimated.  
Recently,  the QOL survey changed from the UCLA-
PCI to the Expanded Prostate Cancer Index 
Composite (EPIC) [18,  19].  The EPIC contains 
more questions concerning urinary and bowel function,  
including,  for example,  urinary and bowel irritation.  
The results from the EPIC emphasize urinary func-
tion.  Frank et al.  [20] report that radiation causes 
signiﬁcantly worse bowel function and bother than 
RRP.  Although RRP resulted in signiﬁcantly worse 
urinary incontinence than BT in Frankʼs study,  the 
opposite was true for urinary irritation.  However,  the 
superiority of sexual issues in the BT group in the 
ﬁrst year after treatment is unquestionable even 
though sexual dysfunction is reported in long-term 
studies [21,  22].
　 The present study might have avoidable biases.  For 
example,  there may be a possible bias due to the inﬂu-
ences of neo-adjuvant hormonal therapy and treatment 
explanations,  which mention the possibility of inconti-
nence in RRP,  and dysuria in BT.  Additionally,  the 
pre-treatment explanations for the patients might also 
aﬀect outcomes in such a QOL study since randomiza-
tion is impossible.  Furthermore,  the present study 
had a short,  12-month observation period; QOL 
results may change during a longer follow-up.  
However,  the changes and diﬀerences in QOL for the 
12 months following surgery are clear.
　 Based on the present results,  brachytherapy is 
recommended for patients with localized low-risk 
prostate cancer eager to maintain sexual function 
immediately after treatment.  Nevertheless,  although 
HRQOL in the early period after treatment is dis-
turbed,  RRP is still a standard treatment modality,  
even from the point of view of QOL.
　 The present results,  therefore,  are useful and 
provide important information when selecting the 
optimal treatment for localized prostate cancer,  
although long-term observations and further surveys 
remain to be conducted.
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